Ciprofibrate - Lipid modification

The PCN recommends the use of fibrates for lipid modification as follows:

Familial hypercholesterolaemia - as per NICE CG71 (updated July 2016) in patients with familial hypercholesterolaemia (FH) with intolerance or contraindications to statins or ezetimibe. Patients should be offered a referral to a specialist with expertise in FH for consideration for treatment with either a bile acid sequestrant (resin), nicotinic acid or a fibrate to reduce their LDL-C concentration. For these patients, fibrates should be considered BLUE (no information sheet) on the traffic light system. Specialists to initiate treatment or make a recommendation for the primary care prescriber to initiate treatment.

Hypertriglyceridaemia - as a treatment option for patients with hypertriglyceridaemia (>10mmol/L).
BLUE traffic light status - Specialists to initiate treatment or make a recommendation for the primary care prescriber to initiate treatment.

Policy statements and further information below.